Nurix Therapeutics, Inc. (NRIX) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	701.9M	84.0M	54.5M	77.0M	38.6M
Cost of Revenue	94.8M	18.9M	221.6M	189.1M	184.5M
Gross Profit	607.2M	65.1M	(167.1M)	(112.2M)	(145.9M)
Operating Expenses
R&D Expense	332.0M	308.2M	221.6M	189.1M	184.5M
SG&A Expense	78.2M	52.7M	45.9M	42.9M	38.0M
General & Admin Expense	78.2M	52.7M	45.9M	42.9M	38.0M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(92.6M)	(10.1M)	(221.6M)	(189.1M)	(184.5M)
Total Operating Expenses	317.5M	350.8M	45.9M	42.9M	38.0M
Cost and Expenses	412.3M	369.6M	267.6M	232.1M	222.5M
Operating Income (EBIT)	289.7M	(285.7M)	(213.0M)	(155.1M)	(183.9M)
Non-Operating
Interest Income	18.6M	22.0M	19.7M	11.1M	3.5M
Interest Expense	—	—	—	—	—
Net Interest Income	18.6M	22.0M	19.7M	11.1M	3.5M
Other Non-Op Income/Expense	18.6M	22.0M	19.7M	11.1M	3.5M
Non-Operating Income (excl Interest)	(18.6M)	(22.0M)	(19.7M)	(11.1M)	(3.5M)
EBT (Pre-Tax Income)	308.2M	(263.7M)	(193.3M)	(143.9M)	(180.4M)
Income Tax Expense	13.3M	760.0K	270.0K	—	—
Bottom Line
Net Income	294.9M	(264.5M)	(193.6M)	(143.9M)	(180.4M)
Earnings from Cont. Ops	294.9M	(264.5M)	(193.6M)	(143.9M)	(180.4M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	294.9M	(264.5M)	(193.6M)	(143.9M)	(180.4M)
Per Share
Basic EPS	$2.51	($3.05)	($2.88)	($2.65)	($3.71)
Diluted EPS	$2.31	($3.05)	($2.88)	($2.65)	($3.71)
Revenue Per Share	$6.29	$0.97	$0.81	$1.42	$0.79
Shares
Basic Shares Outstanding	111.6M	86.7M	67.1M	54.3M	48.6M
Diluted Shares Outstanding	116.2M	86.7M	67.1M	54.3M	48.6M
Profitability Metrics
EBITDA	322.6M	(244.8M)	(176.9M)	(130.3M)	(169.6M)
D&A	14.4M	18.9M	16.4M	13.7M	10.8M
EBIT	308.2M	(263.7M)	(193.3M)	(143.9M)	(180.4M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Aug 1, 2026